KYNTRA BIO, INC. Loss Contingency, New Claims Filed, Number
KYNTRA BIO, INC. (KYNB) reported Loss Contingency, New Claims Filed, Number of 7 ShareholderDerivativ for the 32-month period ending 2024-04-03, per its 10-Q filed 2025-08-11.
Financial Statements › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyNewClaimsFiledNumber · last filed 2026-05-12
- 2021-05-31: Loss Contingency, New Claims Filed, Number 1 month 2.00 PutativeClassAction; Loss Contingency, New Claims Filed, Number 2 month 5.00 PutativeClassAction.
- 2021-04-30: Loss Contingency, New Claims Filed, Number 1 month 3.00 PutativeClassAction.
PutativeClassAction
| Period end | Loss Contingency, New Claims Filed, Number 1 month | Loss Contingency, New Claims Filed, Number 2 month |
|---|---|---|
| 2021-05-31 | 2.00 PutativeClassAction 10-Q · filed 2022-08-08 | 5.00 PutativeClassAction 10-Q · filed 2026-05-12 |
| 2021-04-30 | 3.00 PutativeClassAction 10-Q · filed 2022-08-08 |
ShareholderDerivativ
| Period end | Loss Contingency, New Claims Filed, Number 28 month | Loss Contingency, New Claims Filed, Number 32 month |
|---|---|---|
| 2024-04-03 | 7.00 ShareholderDerivativ 10-Q · filed 2025-08-11 | |
| 2023-12-05 | 6.00 ShareholderDerivativ 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |